These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 37169384)

  • 21. A prospective study of the 6 min walk test as a surrogate marker for haemodynamics in two independent cohorts of treatment-naïve systemic sclerosis-associated pulmonary arterial hypertension.
    Sanges S; Launay D; Rhee RL; Sitbon O; Hachulla É; Mouthon L; Guillevin L; Rottat L; Montani D; De Groote P; Cottin V; Magro P; Prévot G; Bauer F; Bergot E; Chabanne C; Reynaud-Gaubert M; Leroy S; Canuet M; Sanchez O; Gut-Gobert C; Dauphin C; Pison C; Boissin C; Habib G; Clerson P; Conesa F; Cordier JF; Kawut SM; Simonneau G; Humbert M
    Ann Rheum Dis; 2016 Aug; 75(8):1457-65. PubMed ID: 26324844
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Directing therapy in pulmonary arterial hypertension using a target 6 min walk distance.
    Porhownik NR; Myers R; Bshouty Z
    Can Respir J; 2013; 20(2):111-5. PubMed ID: 23616968
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Baseline and follow-up 6-min walk distance and brain natriuretic peptide predict 2-year mortality in pulmonary arterial hypertension.
    Fritz JS; Blair C; Oudiz RJ; Dufton C; Olschewski H; Despain D; Gillies H; Kawut SM
    Chest; 2013 Feb; 143(2):315-323. PubMed ID: 22814814
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and efficacy of transitioning from selexipag to oral treprostinil in pulmonary arterial hypertension: Findings from the ADAPT registry.
    Lachant D; Minkin R; Swisher J; Mogri M; Zolty R; Hwang S; Seaman S; Broderick M; Sahay S
    Pulm Pharmacol Ther; 2023 Oct; 82():102232. PubMed ID: 37451609
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison between the efficacy of combination therapy and monotherapy in connective tissue disease associated pulmonary arterial hypertension: a systematic review and meta-analysis.
    Pan J; Lei L; Zhao C
    Clin Exp Rheumatol; 2018; 36(6):1095-1102. PubMed ID: 29998831
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Echocardiographic Assessment of Right Ventricular Function and Response to Therapy in Pulmonary Arterial Hypertension.
    Shelburne NJ; Parikh KS; Chiswell K; Shaw LK; Sivak J; Arges K; Tomfohr J; Velazquez EJ; Kisslo J; Samad Z; Rajagopal S
    Am J Cardiol; 2019 Oct; 124(8):1298-1304. PubMed ID: 31481176
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study.
    Oudiz RJ; Brundage BH; Galiè N; Ghofrani HA; Simonneau G; Botros FT; Chan M; Beardsworth A; Barst RJ;
    J Am Coll Cardiol; 2012 Aug; 60(8):768-74. PubMed ID: 22818063
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predicting outcomes in pulmonary arterial hypertension based on the 6-minute walk distance.
    Farber HW; Miller DP; McGoon MD; Frost AE; Benton WW; Benza RL
    J Heart Lung Transplant; 2015 Mar; 34(3):362-8. PubMed ID: 25312386
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New perspectives in long-term outcomes in clinical trials of pulmonary arterial hypertension.
    Preston IR; Suissa S; Humbert M
    Eur Respir Rev; 2013 Dec; 22(130):495-502. PubMed ID: 24293465
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness and safety of endothelin receptor antagonists, alone and in combination therapy, in the pulmonary arterial hypertension-connective tissue disease subtype: A systematic review and meta-analysis.
    Shivakumar S; Thynne TR; Mohammadi L; Burdeniuk C; Mangoni AA
    Int J Rheum Dis; 2020 Oct; 23(10):1276-1287. PubMed ID: 32691518
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Bayesian Network Meta-analysis of Add-on Drug Therapies Specific for Pulmonary Arterial Hypertension.
    Petrovič M; Locatelli I
    Ann Pharmacother; 2020 May; 54(5):423-433. PubMed ID: 31735058
    [No Abstract]   [Full Text] [Related]  

  • 32. Follow-Up Functional Class and 6-Minute Walk Distance Identify Long-Term Survival in Pulmonary Arterial Hypertension.
    Heresi GA; Rao Y
    Lung; 2020 Dec; 198(6):933-938. PubMed ID: 33211166
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term safety and tolerability of ambrisentan treatment for pediatric patients with pulmonary arterial hypertension: An open-label extension study.
    Ivy D; Beghetti M; Juaneda-Simian E; Ravindranath R; Lukas MA; Machlitt-Northen S; Scott N; Narita J; Berger RMF
    Eur J Pediatr; 2024 May; 183(5):2141-2153. PubMed ID: 38366267
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of pulmonary arterial hypertension in patients with connective tissue diseases: a systematic review and meta-analysis.
    Erdogan M; Esatoglu SN; Kilickiran Avci B; Hatemi G
    Intern Emerg Med; 2024 Apr; 19(3):731-743. PubMed ID: 38378970
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comorbid conditions and outcomes in patients with pulmonary arterial hypertension: a REVEAL registry analysis.
    Poms AD; Turner M; Farber HW; Meltzer LA; McGoon MD
    Chest; 2013 Jul; 144(1):169-176. PubMed ID: 23348820
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Baseline NT-proBNP correlates with change in 6-minute walk distance in patients with pulmonary arterial hypertension in the pivotal inhaled treprostinil study TRIUMPH-1.
    Frantz RP; McDevitt S; Walker S
    J Heart Lung Transplant; 2012 Aug; 31(8):811-6. PubMed ID: 22759797
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hemodynamics and risk assessment 2 years after the initiation of upfront ambrisentan‒tadalafil in pulmonary arterial hypertension.
    D'Alto M; Badagliacca R; Lo Giudice F; Argiento P; Casu G; Corda M; Correale M; Ghio S; Greco A; Lattanzio M; Mercurio V; Paciocco G; Papa S; Prediletto R; Romeo E; Russo MG; Tayar A; Vitulo P; Vizza CD; Golino P; Naeije R
    J Heart Lung Transplant; 2020 Dec; 39(12):1389-1397. PubMed ID: 32933828
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Contemporary risk scores predict clinical worsening in pulmonary arterial hypertension - An analysis of FREEDOM-EV.
    Benza RL; Gomberg-Maitland M; Farber HW; Vizza CD; Broderick M; Holdstock L; Nelsen AC; Deng C; Rao Y; White RJ
    J Heart Lung Transplant; 2022 Nov; 41(11):1572-1580. PubMed ID: 36117055
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. A Double-Blind Placebo-controlled Clinical Trial.
    White RJ; Jerjes-Sanchez C; Bohns Meyer GM; Pulido T; Sepulveda P; Wang KY; Grünig E; Hiremath S; Yu Z; Gangcheng Z; Yip WLJ; Zhang S; Khan A; Deng CQ; Grover R; Tapson VF;
    Am J Respir Crit Care Med; 2020 Mar; 201(6):707-717. PubMed ID: 31765604
    [No Abstract]   [Full Text] [Related]  

  • 40. Clinical trial designs in PAH: shifting from functional measurements to long-term clinical outcomes.
    Studer SM; Gilkin RJ
    Am J Manag Care; 2014 Mar; 20(6 Suppl):S115-22. PubMed ID: 24716456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.